학술논문
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 8/20/2023, Vol. 41 Issue 24, p4014-4024, 13p
Subject
Language
ISSN
0732183X